JOINTstat™ is a blood test that measures the levels of 14-3-3η protein and is used in conjunction with clinical assessments to assist with RA diagnosis.
14-3-3η’s role in RA was first described in the Journal of Rheumatology in 2007 by Canadian academic scientists and clinicians at the University of British Columbia and University of Alberta. Since then, this novel biomarker has been clinically evaluated by leading international investigators in over 3000 patients in multiple studies. Data has been presented at EULAR and ACR in over 50 conference proceedings through either oral or poster presentations. During 2014, five articles in peer-reviewed journals have published describing the clinical utility of 14-3-3η measurements.
In the United States, the 14-3-3η test is available for clinical use through Quest Diagnostics and RDL Reference Laboratory, as an RA diagnostic panel including RF and anti-CCP, and as a standalone test to facilitate 14-3-3η serial measurements for ongoing patient management.
JOINTstat™ is Health Canada approved for clinical use and was launched by LifeLabs Medical Laboratories in December 2014.
In Japan, JOINTstat™ is distributed by Medical & Biological Lifesciences (MBL) Co, Ltd., Japan.